Solara Pharma shareholders approve Mohanraj Sanjeevi as Whole-time Director
Solara Active Pharma Sciences Limited shareholders approved Mr. Mohanraj Sanjeevi's appointment as Whole-time Director. The resolution passed via remote e-voting. His tenure is three years from Jan 1, 2026, with ₹85 lakh fixed and ₹15 lakh variable annual pay.
The appointment of a Whole-time Director is significant for the company's management structure and future operations, impacting strategic decisions and execution.
The shareholders have approved a key management appointment, which is a positive development for the company's governance and operational continuity.
Solara Active Pharma Sciences Limited announced that shareholders have approved the appointment of Mr. Mohanraj Sanjeevi as a Whole-time Director (Executive Director) of the Company through postal ballot via remote e-voting. The resolution was passed with the requisite majority.
The appointment is for a period of three years, effective from January 01, 2026, to December 31, 2028. Mr. Sanjeevi's remuneration will include a fixed component of ₹85,00,000 per annum and a variable pay of ₹15,00,000 per annum, along with other benefits as per company policy, including ESOPs.
The postal ballot notice was dispatched on February 04, 2026, and the remote e-voting period commenced on February 05, 2026, and concluded on March 06, 2026. The scrutinizer's report, dated March 10, 2026, confirmed that the resolution was deemed to be passed with the requisite majority on March 06, 2026. The company will make the voting results and scrutinizer's report available on its website.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.